Plasma purine nucleoside phosphorylase in cancer patients

Background: Purine nucleoside phosphorylase (PNP) is the purine salvage enzyme that converts guanosine to guanine and inosine to hypoxanthine. Methods: 279 samples from patients with differing cancers were collected during treatment at both pre- and post-dose stages for plasma PNP activity and compa...

Full description

Saved in:
Bibliographic Details
Published in:Clinica chimica acta 2004-06, Vol.344 (1), p.109-114
Main Authors: Roberts, Elton L.L., Newton, Russell P., Axford, Alan T.
Format: Article
Language:English
Subjects:
Antineoplastic Agents - pharmacology
Antineoplastic Agents - therapeutic use
Cancer
Case-Control Studies
HPLC method
Humans
Neoplasms - blood
Neoplasms - enzymology
Plasma
Purine nucleoside phosphorylase
Purine-Nucleoside Phosphorylase - blood
Purine-Nucleoside Phosphorylase - drug effects
Purine-Nucleoside Phosphorylase - standards
Reference Values
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background: Purine nucleoside phosphorylase (PNP) is the purine salvage enzyme that converts guanosine to guanine and inosine to hypoxanthine. Methods: 279 samples from patients with differing cancers were collected during treatment at both pre- and post-dose stages for plasma PNP activity and compared with a normal population. Results: Normal plasma PNP activity was found to be 3.2±1.4 U/l ( n=55) as compared with the cancer patients (pre-dose 12.3±7.4 U/l [ n=215] and post-dose 11.2±5.9 U/l [ n=64]). Levels of plasma PNP did not differ greatly between the different cancer types but were on average four times greater than that found in the reference population.
ISSN:0009-8981
1873-3492
DOI:10.1016/j.cccn.2004.02.008